Role and importance of biochemical markers in clinical cardiology

被引:110
作者
Panteghini, M [1 ]
机构
[1] Univ Brescia, Spedali Civili Hosp, Clin Chem Lab 1, I-25125 Brescia, Italy
关键词
biological markers; diagnosis; myocardial infarction; troponin;
D O I
10.1016/j.ehj.2004.04.026
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This paper reviews the current contribution of the biochemical marker determination to clinical cardiology and discusses some important developments in this field. Biochemical markers play a pivotal rote in the diagnosis and management of patients with acute coronary syndrome (ACS), as witnessed by the incorporation of cardiac troponins into new international guidelines for patients with ACS and in the redefinition of myocardial infarction. Despite the success of cardiac troponins, there is still a need for the development of early markers that can reliably rule out ACS from the emergency room at presentation and also detect myocardial ischaemia in the absence of irreversible myocyte injury. Under investigation are two classes of indicators: markers of early injury/ischaemia and markers of inflammation and coronary plaque instability and disruption. Finally, with the characterisation of the cardiac natriuretic peptides, Laboratory Medicine is also assuming a role in the assessment of cardiac function. (C) 2004 Published by Elsevier Ltd on behalf of The European Society of Cardiology.
引用
收藏
页码:1187 / 1196
页数:10
相关论文
共 124 条
[1]  
Adams JE, 2002, CIRCULATION, V106, P532
[2]   Myocardial infarction redefined -: A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction [J].
Alpert, JS ;
Antman, E ;
Apple, F ;
Armstrong, PW ;
Bassand, JP ;
de Luna, AB ;
Beller, G ;
Breithardt, G ;
Chaitman, BR ;
Clemmensen, P ;
Falk, E ;
Fishbein, MC ;
Galvani, M ;
Garson, A ;
Grines, C ;
Hamm, C ;
Hoppe, U ;
Jaffe, A ;
Katus, H ;
Kjekshus, J ;
Klein, W ;
Klootwijk, P ;
Lenfant, C ;
Levy, D ;
Levy, RI ;
Luepker, R ;
Marcus, F ;
Näslund, U ;
Ohman, M ;
Pahlm, O ;
Poole-Wilson, P ;
Popp, R ;
Pyörälä, K ;
Ravkilde, J ;
Rehnquist, N ;
Roberts, W ;
Roberts, R ;
Roelandt, J ;
Rydén, L ;
Sans, S ;
Simoons, ML ;
Thygesen, K ;
Tunstall-Pedoe, H ;
Underwood, R ;
Uretsky, BF ;
de Werf, FV ;
Voipio-Pulkki, LM ;
Wagner, G ;
Wallentin, L ;
Wijns, W .
EUROPEAN HEART JOURNAL, 2000, 21 (18) :1502-1513
[3]   Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes [J].
Ammann, P ;
Maggiorini, M ;
Bertel, O ;
Haenseler, E ;
Joller-Jemelka, HI ;
Oechslin, E ;
Minder, EI ;
Rickli, H ;
Fehr, T .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (11) :2004-2009
[4]   Platelet-derived CD40L -: The switch-hitting player of cardiovascular disease [J].
André, P ;
Nannizzi-Alaimo, L ;
Prasad, SK ;
Phillips, DR .
CIRCULATION, 2002, 106 (08) :896-899
[5]   Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology American College of Cardiology consensus recommendations [J].
Apple, FS ;
Quist, HE ;
Doyle, PJ ;
Otto, AP ;
Murakami, MM .
CLINICAL CHEMISTRY, 2003, 49 (08) :1331-1336
[6]   European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: How to use existing assays clinically and for clinical trials [J].
Apple, FS ;
Wu, AHB ;
Jaffe, AS .
AMERICAN HEART JOURNAL, 2002, 144 (06) :981-986
[7]   Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease [J].
Apple, FS ;
Murakami, MM ;
Pearce, LA ;
Herzog, CA .
CIRCULATION, 2002, 106 (23) :2941-2945
[8]  
Apple FS, 2002, CLIN CHEM, V48, P1097
[9]  
Apple FS, 1999, CLIN CHEM, V45, P18
[10]  
Apple FS, 2001, CLIN CHEM, V47, P377